Radiotherapy Equipment to Last a Lifetime

Medical equipment professionals often debate whether machines are useful past their “expiration” date. Newer radiation therapy equipment is touted to last seven or eight years, noting that it took roughly seven years to design and program before its release, doubling its age instantaneously. Therefore, the technology, software, and knowledge associated with a 14-year-old device is severely outdated. 

However, this thinking is not necessarily true, as there are machines over 20 years old that are operating safely and reliably. In Latin America, a Varian 6X linear accelerator has been treating patients for more than 40 years.

Since 1953, a GE MaximaR 100 X-Ray Device (also known as a Superficial Unit) has been working at a hospital in the United States. For almost 70 years, this unit has helped treat skin cancer patients by producing mild doses of radiation to destroy cancer cells while preserving the surrounding healthy tissue. This machine is still being manufactured for use in dermatology and radiation oncology clinics.

In the Caribbean, a physician at a radiation oncology center said, “Our 2003 Varian 21EX linear accelerator treats over 50 patients per day. It has all the features we want including RapidArc. The 21EX has successfully treated thousands of patients.”

These machines are well-built and are fully capable of lasting longer than seven or eight years. Certain companies purposefully underestimate the life of their linear accelerators to drive sales and increase new model usage. Also, many refurbished linear accelerators use the exact same technology as the current market models. 

Are you looking to purchase a refurbished linear accelerator or have yours repaired? Contact RadParts today.

RadParts is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

 

Particle Accelerators Create Potential Cancer Treatment in Lansing

A Lansing company called Niowave has begun producing actinium-225, a silvery metal isotope that barely exists on Earth, with a superconducting linear accelerator. The reason? This isotope is a promising cancer treatment; however, researchers don’t know its full potential due to the absence of clinical trials. 

Niowave has secured a $5 million deal with Fusion Pharmaceuticals to start production in 2024.  Between Russia, the United States, Germany, and Canada, there are only two curies (unit of measurement for radioactive materials) of actinium-225. Niowave plans on making one curie per week. 

In 2019, the federal government gave Niowave $15 million, and another $13 million last year, to produce molybdenum 99, which is used for medical imaging. Since other countries subsidize its production, making a profit from molybdenum 99 is tricky. 

After working with uranium for years, the federal government determined Niowave could function safely with another highly radioactive element, radium, to create actinium-225. 

Cancer therapy isotopes emit beta particles, which can destroy cancer cells but also kill healthy cells around them. Actinium-225 delivers more targeted alpha particles, which can emit more energy at a shorter distance.

Justin Wilson, an associate professor of chemistry and chemical biology at Cornell University said, “If you can get those alpha particles to the cancer cells, they have the capability of doing more damage but in a more confined region. Which, in theory, could prevent hitting healthy cells that maybe aren’t part of the small metastatic lesion.” 

Eric Burak, chief technical officer at Fusion Pharmaceuticals, states that they are working on formulating three separate drugs that use actinium-225. He said the isotope is “One of the rarest elements in the entire planet, and, with more companies interested in its therapeutic potential, everyone is scrambling for actinium supply.” 

Fusion Pharmaceuticals are investing $5 million to help Niowave create actinium-225 in exchange for a guaranteed share of the end result. 

Niowave’s superconducting linear accelerator has been moved to a concrete room as radium is extremely radioactive. 

_______________________________

RadParts is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/

 

Novel Cancer Treatment Headed to McLaren Flint

An innovative new technology headed to Flint will be used to treat cancer with proton therapy. The McLaren Proton Therapy Center is the first to receive the new machine that treats patients upright, enabling cancer treatment with more precision. 

Leo Cancer Care developed the proton therapy called “Marie,” which will take up less space yet provide more accurate treatments since there will be less organ movement. 

The Proton Therapy Center in Flint will receive the first two upright units and be used within the next two years, pending FDA approval. The largest proton center in Michigan, the new machine will allow more patients to be treated. 

According to a news release from McLaren, proton therapy is a type of radiation therapy that uses protons to accurately target tumor cells and leave healthy surrounding cells undamaged.

Stephen Towe, CEO of Leo Cancer Care, said, “The goal of Leo Cancer Care and McLaren Proton Therapy Center’s collaboration is to bring proton therapy to more patients, and we know there are clear advantages with proton therapy. The McLaren Proton Therapy Center is well-positioned to become the first to potentially treat patients with the revolutionary Leo Cancer Care technology.”

Construction to add the “Marie” units to the Proton Therapy Center in Flint will start in the spring of 2023 and be fully operational by the fall of 2024.  

--------------------------------------------------------

RadParts is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/